Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin + pembrolizumab versus platinum-based chemotherapy in previously untreated HER2-expressing advanced urothelial carcinoma
NL-OMON56748Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of disitamab vedotin and pembrolizumab in transitional cell carcinoma (TCC), bladder cancer and kidney cancer (2 arms), sponsored by Pfizer. Primary endpoints: Progression-free survival, Overall survival and 1 more. Started Jun 2025; status: recruiting.
02
Drugs
disitamab vedotinpembrolizumab
03
Conditions
transitional cell carcinoma (TCC)bladder cancerkidney cancer
Beyond the preview
Go deeper on NL-OMON56748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56748.